US regulator rejects Fortress Biotech’s experimental pediatric medicineÂ
The US regulator has declined to approve an experimental pediatric drug of Fortress Biotech Inc., an American biotechnology company, due to certain production.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
The US regulator has declined to approve an experimental pediatric drug of Fortress Biotech Inc., an American biotechnology company, due to certain production.
Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in.
Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.
HQ Team July 16, 2025: AstraZeneca Plc’s investigational drug to treat AL amyloidosis, a rare and serious disease affecting the heart and kidneys,.
HQ Team June 4, 2025: British-Swedish AstraZeneca Plc.’s investigational pill to treat an advanced breast cancer has reduced the chance of worsening the.
Eli Lilly and Company cut the prices of its weight-loss drug Zepbound, available in single-dose vials, in a bid to end compounding companies from.
The US Food and Drug Administration has approved Johnson & Johnson’s nasal spray in adults who have had an inadequate response to at.
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.
ohnson & Johnson paused its rollout of a heart device to treat atrial fibrillation “out of an abundance of caution,” as it probes four.
HQ Team December 11, 2024: The U.S. Food and Drug Administration (FDA) has announced a halt to all clinical trials for respiratory syncytial.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com